MersV1, PubMed, Checkpoint, bibRecord, 001D53

RNA synthesis by reverse direction process: phosphoramidites and high purity RNAs and introduction of ligands, chromophores, and modifications at 3'-end.

Identifieur interne : 001D53 ( PubMed/Checkpoint ); précédent : 001D52; suivant : 001D54

RNA synthesis by reverse direction process: phosphoramidites and high purity RNAs and introduction of ligands, chromophores, and modifications at 3'-end.

Auteurs : Suresh C. Srivastava [États-Unis] ; Divya Pandey ; Naveen P. Srivastava ; Satya P. Bajpai

Source :

Current protocols in nucleic acid chemistry [ 1934-9289 ] ; 2011.

RBID : pubmed:21638272

Descripteurs français

English descriptors

KwdEn :
- Base Sequence, Chromatography, High Pressure Liquid, Ligands, Molecular Structure, Oligoribonucleotides (chemistry), Organophosphorus Compounds (chemistry), Organosilicon Compounds (chemistry), RNA (chemical synthesis), Sequence Analysis, RNA.
MESH :
- chemical , chemical synthesis : RNA.
- chemical , chemistry : Oligoribonucleotides, Organophosphorus Compounds, Organosilicon Compounds.
- chemical : Ligands.
- Base Sequence, Chromatography, High Pressure Liquid, Molecular Structure, Sequence Analysis, RNA.

Abstract

We have synthesized and studied the coupling properties of 3'-DMT-5'-CE phosphoramidites. The coupling efficiency per step surpasses 99% in the reverse-direction synthesis methodology, leading to high-purity RNA in a large number of 20- to 21-mers and long-chain oligonucleotides. Our data show that 5'→3' direction synthesis has a distinct advantage compared to the conventional method. As a result, this method of RNA synthesis is expected to be a very useful and practical method of choice for therapeutic-grade RNA. The phosphoramidites, Rev-A-n-bz, Rev-C-n-bz, Rev-C-n-ac, Rev-G-n-ac, and Rev-rU are routinely produced with an HPLC purity of greater than 98% and (31)P NMR purity greater than 99.5%.

DOI: 10.1002/0471142700.nc0320s45
PubMed: 21638272

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001E72
to stream PubMed, to step Curation: 001E72

Links to Exploration step

pubmed:21638272

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">RNA synthesis by reverse direction process: phosphoramidites and high purity RNAs and introduction of ligands, chromophores, and modifications at 3'-end.</title>
<author><name sortKey="Srivastava, Suresh C" sort="Srivastava, Suresh C" uniqKey="Srivastava S" first="Suresh C" last="Srivastava">Suresh C. Srivastava</name>
<affiliation wicri:level="2"><nlm:affiliation>ChemGenes Corp., Wilmington, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ChemGenes Corp., Wilmington, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pandey, Divya" sort="Pandey, Divya" uniqKey="Pandey D" first="Divya" last="Pandey">Divya Pandey</name>
</author>
<author><name sortKey="Srivastava, Naveen P" sort="Srivastava, Naveen P" uniqKey="Srivastava N" first="Naveen P" last="Srivastava">Naveen P. Srivastava</name>
</author>
<author><name sortKey="Bajpai, Satya P" sort="Bajpai, Satya P" uniqKey="Bajpai S" first="Satya P" last="Bajpai">Satya P. Bajpai</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21638272</idno>
<idno type="pmid">21638272</idno>
<idno type="doi">10.1002/0471142700.nc0320s45</idno>
<idno type="wicri:Area/PubMed/Corpus">001E72</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E72</idno>
<idno type="wicri:Area/PubMed/Curation">001E72</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E72</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001D53</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001D53</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">RNA synthesis by reverse direction process: phosphoramidites and high purity RNAs and introduction of ligands, chromophores, and modifications at 3'-end.</title>
<author><name sortKey="Srivastava, Suresh C" sort="Srivastava, Suresh C" uniqKey="Srivastava S" first="Suresh C" last="Srivastava">Suresh C. Srivastava</name>
<affiliation wicri:level="2"><nlm:affiliation>ChemGenes Corp., Wilmington, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ChemGenes Corp., Wilmington, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pandey, Divya" sort="Pandey, Divya" uniqKey="Pandey D" first="Divya" last="Pandey">Divya Pandey</name>
</author>
<author><name sortKey="Srivastava, Naveen P" sort="Srivastava, Naveen P" uniqKey="Srivastava N" first="Naveen P" last="Srivastava">Naveen P. Srivastava</name>
</author>
<author><name sortKey="Bajpai, Satya P" sort="Bajpai, Satya P" uniqKey="Bajpai S" first="Satya P" last="Bajpai">Satya P. Bajpai</name>
</author>
</analytic>
<series><title level="j">Current protocols in nucleic acid chemistry</title>
<idno type="eISSN">1934-9289</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Base Sequence</term>
<term>Chromatography, High Pressure Liquid</term>
<term>Ligands</term>
<term>Molecular Structure</term>
<term>Oligoribonucleotides (chemistry)</term>
<term>Organophosphorus Compounds (chemistry)</term>
<term>Organosilicon Compounds (chemistry)</term>
<term>RNA (chemical synthesis)</term>
<term>Sequence Analysis, RNA</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN (synthèse chimique)</term>
<term>Analyse de séquence d'ARN</term>
<term>Chromatographie en phase liquide à haute performance</term>
<term>Composés organiques du phosphore ()</term>
<term>Composés organiques du silicium ()</term>
<term>Ligands</term>
<term>Oligoribonucléotides ()</term>
<term>Structure moléculaire</term>
<term>Séquence nucléotidique</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>RNA</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Oligoribonucleotides</term>
<term>Organophosphorus Compounds</term>
<term>Organosilicon Compounds</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Ligands</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>ARN</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Base Sequence</term>
<term>Chromatography, High Pressure Liquid</term>
<term>Molecular Structure</term>
<term>Sequence Analysis, RNA</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse de séquence d'ARN</term>
<term>Chromatographie en phase liquide à haute performance</term>
<term>Composés organiques du phosphore</term>
<term>Composés organiques du silicium</term>
<term>Ligands</term>
<term>Oligoribonucléotides</term>
<term>Structure moléculaire</term>
<term>Séquence nucléotidique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have synthesized and studied the coupling properties of 3'-DMT-5'-CE phosphoramidites. The coupling efficiency per step surpasses 99% in the reverse-direction synthesis methodology, leading to high-purity RNA in a large number of 20- to 21-mers and long-chain oligonucleotides. Our data show that 5'→3' direction synthesis has a distinct advantage compared to the conventional method. As a result, this method of RNA synthesis is expected to be a very useful and practical method of choice for therapeutic-grade RNA. The phosphoramidites, Rev-A-n-bz, Rev-C-n-bz, Rev-C-n-ac, Rev-G-n-ac, and Rev-rU are routinely produced with an HPLC purity of greater than 98% and (31)P NMR purity greater than 99.5%.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21638272</PMID>
<DateCompleted><Year>2011</Year>
<Month>09</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>10</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1934-9289</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>Chapter 3</Volume>
<PubDate><Year>2011</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Current protocols in nucleic acid chemistry</Title>
<ISOAbbreviation>Curr Protoc Nucleic Acid Chem</ISOAbbreviation>
</Journal>
<ArticleTitle>RNA synthesis by reverse direction process: phosphoramidites and high purity RNAs and introduction of ligands, chromophores, and modifications at 3'-end.</ArticleTitle>
<Pagination><MedlinePgn>Unit3.20</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/0471142700.nc0320s45</ELocationID>
<Abstract><AbstractText>We have synthesized and studied the coupling properties of 3'-DMT-5'-CE phosphoramidites. The coupling efficiency per step surpasses 99% in the reverse-direction synthesis methodology, leading to high-purity RNA in a large number of 20- to 21-mers and long-chain oligonucleotides. Our data show that 5'→3' direction synthesis has a distinct advantage compared to the conventional method. As a result, this method of RNA synthesis is expected to be a very useful and practical method of choice for therapeutic-grade RNA. The phosphoramidites, Rev-A-n-bz, Rev-C-n-bz, Rev-C-n-ac, Rev-G-n-ac, and Rev-rU are routinely produced with an HPLC purity of greater than 98% and (31)P NMR purity greater than 99.5%.</AbstractText>
<CopyrightInformation>© 2011 by John Wiley & Sons, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Srivastava</LastName>
<ForeName>Suresh C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo><Affiliation>ChemGenes Corp., Wilmington, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pandey</LastName>
<ForeName>Divya</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Srivastava</LastName>
<ForeName>Naveen P</ForeName>
<Initials>NP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bajpai</LastName>
<ForeName>Satya P</ForeName>
<Initials>SP</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Curr Protoc Nucleic Acid Chem</MedlineTA>
<NlmUniqueID>101287865</NlmUniqueID>
<ISSNLinking>1934-9270</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009843">Oligoribonucleotides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009943">Organophosphorus Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017646">Organosilicon Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C434331">phosphoramidite</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C009660">t-butyldimethylsilyl compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>63231-63-0</RegistryNumber>
<NameOfSubstance UI="D012313">RNA</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009843" MajorTopicYN="N">Oligoribonucleotides</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009943" MajorTopicYN="N">Organophosphorus Compounds</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017646" MajorTopicYN="N">Organosilicon Compounds</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>6</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>6</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>10</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21638272</ArticleId>
<ArticleId IdType="doi">10.1002/0471142700.nc0320s45</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
</region>
</list>
<tree><noCountry><name sortKey="Bajpai, Satya P" sort="Bajpai, Satya P" uniqKey="Bajpai S" first="Satya P" last="Bajpai">Satya P. Bajpai</name>
<name sortKey="Pandey, Divya" sort="Pandey, Divya" uniqKey="Pandey D" first="Divya" last="Pandey">Divya Pandey</name>
<name sortKey="Srivastava, Naveen P" sort="Srivastava, Naveen P" uniqKey="Srivastava N" first="Naveen P" last="Srivastava">Naveen P. Srivastava</name>
</noCountry>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Srivastava, Suresh C" sort="Srivastava, Suresh C" uniqKey="Srivastava S" first="Suresh C" last="Srivastava">Suresh C. Srivastava</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D53 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001D53 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:21638272
   |texte=   RNA synthesis by reverse direction process: phosphoramidites and high purity RNAs and introduction of ligands, chromophores, and modifications at 3'-end.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:21638272" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

RNA synthesis by reverse direction process: phosphoramidites and high purity RNAs and introduction of ligands, chromophores, and modifications at 3'-end.

RNA synthesis by reverse direction process: phosphoramidites and high purity RNAs and introduction of ligands, chromophores, and modifications at 3'-end.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki